Dezocine alleviates cancer-induced bone pain and suppresses intraosseous tumor growth in renal cell carcinoma via the NAMPT/NAD+ axis
Molecular Pain · 2026-06 · 22
DOI: 10.1177/17448069261460286 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pain, online erschienen am 05.06.2026. Verfasst von Lijun Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, The Affiliated People's Hospital of Ningbo University, Ningbo, China. Hauptthemen laut MEDLINE: Nicotinamide Phosphoribosyltransferase, Bone Neoplasms, NAD, Cancer Pain. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Bone metastasis–associated pain is a major cause of morbidity in advanced renal cell carcinoma (RCC), and effective therapies that concurrently mitigate pain and intraosseous tumor burden remain limited. Here, we evaluated dezocine as a potential dual-action agent and explored the involvement of the NAMPT/NAD + axis. In 786-O cells, dezocine dose-dependently suppressed proliferation (IC 50 = 73.6 μM), clonogenicity and increased apoptosis, accompanied by reduced NAMPT expression and a decreased NAD + /NADH ratio. Pharmacological rescue with the NAMPT activator SBI-797812 partially reversed these effects. In vivo, using an intra-tibial RCC cell inoculation model that recapitulates osteolysis and cancer-induced bone pain (CIBP), dezocine alleviated mechanical allodynia and thermal hyperalgesia, and reduced osteolytic bone destruction and intraosseous tumor progression; co-administration of SBI-797812 partially attenuated these effects ( n = 6). Tumor tissues from dezocine-treated mice showed decreased Ki67 and NAMPT, increased cleaved caspase-3, and enhanced AMPK phosphorylation, consistent with metabolic stress–associated apoptosis. Collectively, these findings suggest that dezocine may provide dual analgesic and antitumor benefits in intraosseous RCC lesions, at least in part by suppressing the NAMPT/NAD + axis, supporting further translational evaluation for bone metastasis–associated pain management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, The Affiliated People's Hospital of Ningbo University, Ningbo, China.
ORCID-Profile: Lijun Huang
Zitieren
APA
Huang, L., Hu, C., Shao, Y., & Zhao, L. (2026). Dezocine alleviates cancer-induced bone pain and suppresses intraosseous tumor growth in renal cell carcinoma via the NAMPT/NAD+ axis. Molecular Pain, 22. https://doi.org/10.1177/17448069261460286
Vancouver
Huang L, Hu C, Shao Y, Zhao L. Dezocine alleviates cancer-induced bone pain and suppresses intraosseous tumor growth in renal cell carcinoma via the NAMPT/NAD+ axis. Molecular Pain. 2026;22. doi:10.1177/17448069261460286
BibTeX
@article{Huang2026,
author = {Huang, Lijun and Hu, Cixian and Shao, Ya and Zhao, Liming},
title = {Dezocine alleviates cancer-induced bone pain and suppresses intraosseous tumor growth in renal cell carcinoma via the NAMPT/NAD+ axis},
journal = {Molecular Pain},
year = {2026},
volume = {22},
doi = {10.1177/17448069261460286}
}
EUVIMED